Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

Brentuximab vedotin is indicated for 'the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma'.

Brentuximab vedotin has been available to patients in England through the Cancer Drugs Fund since April 2013 for relapsed or refractory systemic anaplastic large cell lymphoma.

The recommended dose is 1.8 mg/kg administered by intravenous infusion over 30 minutes every 3 weeks.

The price of brentuximab vedotin is £2,500 for a 50‑mg vial (excluding VAT; British national formulary accessed August 2017).

Takeda has agreed a commercial access agreement with NHS England in which a discount is applied at the point of purchase or invoice for brentuximab vedotin. The financial terms of the agreement are commercial in confidence.